Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Summary

This is a phase I study of combination immunotherapy with IFN-γ and the PD-1 inhibitor nivolumab in patients with advanced solid tumors who have progressed on at least one prior systemic therapy, which may include prior immunotherapy.

Timeline

Start

2015-12-11

Primary completion

2019-06-12

Completion

2019-06-12

Publications

• Zibelman M, MacFarlane AW 4th, Costello K, McGowan T, O'Neill J, Kokate R, Borghaei H, Denlinger CS, Dotan E, Geynisman DM, Jain A, Martin L, Obeid E, Devarajan K, Ruth K, Alpaugh RK, Dulaimi EA, Cukierman E, Einarson M, Campbell KS, Plimack ER. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. Nat Commun. 2023 Jul 27;14(1):4513. doi: 10.1038/s41467-023-40028-z.

Drugs

Indications